Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1.
作者信息
Uraki Ryuta, Ito Mutsumi, Kiso Maki, Yamayoshi Seiya, Iwatsuki-Horimoto Kiyoko, Sakai-Tagawa Yuko, Furusawa Yuri, Imai Masaki, Koga Michiko, Yamamoto Shinya, Adachi Eisuke, Saito Makoto, Tsutsumi Takeya, Otani Amato, Kashima Yukie, Kikuchi Tetsuhiro, Yotsuyanagi Hiroshi, Suzuki Yutaka, Kawaoka Yoshihiro
机构信息
Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
出版信息
Lancet Infect Dis. 2023 May;23(5):525-526. doi: 10.1016/S1473-3099(23)00132-9. Epub 2023 Mar 7.
Abstract
摘要
相似文献
1
Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1.抗病毒药物和二价mRNA疫苗对SARS-CoV-2毒株CH.1.1的疗效
Lancet Infect Dis. 2023 May;23(5):525-526. doi: 10.1016/S1473-3099(23)00132-9. Epub 2023 Mar 7.
2
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.二价 SARS-CoV-2 mRNA 疫苗提高中和广度并预防小鼠感染奥密克戎变异株 BA.5。
Nat Med. 2023 Jan;29(1):247-257. doi: 10.1038/s41591-022-02092-8. Epub 2022 Oct 20.
3
Effectiveness of Bivalent Omicron-Containing Booster Vaccines against SARS-CoV-2 Omicron Variant among Individuals with and without Prior SARS-CoV-2 Infection.二价奥密克戎含株加强疫苗对有和无既往 SARS-CoV-2 感染个体的 SARS-CoV-2 奥密克戎变异株的有效性。
Viruses. 2023 Aug 17;15(8):1756. doi: 10.3390/v15081756.
4
Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models.在雌性小动物模型中，未修饰的二价 mRNA 疫苗对 SARS-CoV-2 变体的功效。
Nat Commun. 2023 Feb 13;14(1):816. doi: 10.1038/s41467-023-36110-1.
5
New SARS-CoV-2 Variants Challenge Vaccines Protection.新型新冠病毒变种对疫苗保护构成挑战。
AIDS Rev. 2021 Feb 22;23(1):57-58. doi: 10.24875/AIDSRev.M21000040.
6
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.SARS-CoV-2/COVID-19 大流行管理的潜在治疗靶点和疫苗开发：近期进展综述。
Front Immunol. 2021 Jun 30;12:658519. doi: 10.3389/fimmu.2021.658519. eCollection 2021.
7
SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.养老院居民接种二价 COVID-19 疫苗后对原始 SARS-CoV-2 株和奥密克戎 BA.1 和 BA.4/BA.5 变异株的 SARS-CoV-2 抗体反应 - 俄亥俄州和罗得岛，2022 年 9 月至 11 月。
MMWR Morb Mortal Wkly Rep. 2023 Jan 27;72(4):100-106. doi: 10.15585/mmwr.mm7204a4.
8
SARS-CoV-2 rebound with and without antivirals.有或无抗病毒药物情况下的新型冠状病毒2型反弹
Lancet Infect Dis. 2023 Jun;23(6):637-639. doi: 10.1016/S1473-3099(23)00063-4. Epub 2023 Feb 13.
9
SARS-CoV-2 Proteins: Are They Useful as Targets for COVID-19 Drugs and Vaccines?SARS-CoV-2 蛋白：它们是否可作为 COVID-19 药物和疫苗的靶点？
Curr Mol Med. 2022;22(1):50-66. doi: 10.2174/1566524021666210223143243.
10
Three, four or more: what's the magic number for booster shots?三剂、四剂还是更多剂：加强针的神奇数字是多少？
Nature. 2022 Feb;602(7895):17-18. doi: 10.1038/d41586-022-00200-9.
引用本文的文献
1
Drug susceptibility and the potential for drug-resistant SARS-CoV-2 emergence in immunocompromised animals.免疫功能低下动物中药物敏感性及耐药性严重急性呼吸综合征冠状病毒2出现的可能性。
iScience. 2024 Aug 17;27(9):110729. doi: 10.1016/j.isci.2024.110729. eCollection 2024 Sep 20.
2
High Transferability of Neutralizing Antibodies against SARS-CoV-2 to Umbilical Cord Blood in Pregnant Women Vaccinated with BNT162b2 XBB.1.5: A Retrospective Cohort Study.接种BNT162b2 XBB.1.5的孕妇体内抗SARS-CoV-2中和抗体向脐带血的高转移性：一项回顾性队列研究
Infect Dis Rep. 2024 May 27;16(3):481-490. doi: 10.3390/idr16030036.
3
Clustering analysis for the evolutionary relationships of SARS-CoV-2 strains.SARS-CoV-2 株系进化关系的聚类分析。
Sci Rep. 2024 Mar 18;14(1):6428. doi: 10.1038/s41598-024-57001-5.
4
Zoonosis and zooanthroponosis of emerging respiratory viruses.新发呼吸道病毒的人畜共患病和动物源人兽共患病。
Front Cell Infect Microbiol. 2024 Jan 5;13:1232772. doi: 10.3389/fcimb.2023.1232772. eCollection 2023.
5
Analysis of the protective efficacy of approved COVID-19 vaccines against Omicron variants and the prospects for universal vaccines.分析已获批的 COVID-19 疫苗对奥密克戎变异株的保护效力和通用疫苗的前景。
Front Immunol. 2023 Nov 27;14:1294288. doi: 10.3389/fimmu.2023.1294288. eCollection 2023.
6
Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations.二价新冠疫苗接种者对BQ.1.1、BN.1和XBB.1的中和活性：按既往感染类型和疫苗配方进行比较
Vaccines (Basel). 2023 Aug 4;11(8):1320. doi: 10.3390/vaccines11081320.
7
The effects of amino acid substitution of spike protein and genomic recombination on the evolution of SARS-CoV-2.刺突蛋白的氨基酸取代和基因组重组对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）进化的影响。
Front Microbiol. 2023 Jul 25;14:1228128. doi: 10.3389/fmicb.2023.1228128. eCollection 2023.
8
In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir.体外和体内鉴定恩赛特韦对 SARS-CoV-2 的耐药性。
Nat Commun. 2023 Jul 15;14(1):4231. doi: 10.1038/s41467-023-40018-1.
9
Striking antibody evasion of SARS-CoV-2 Omicron sub-lineages BQ.1.1, XBB.1 and CH.1.1.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎亚谱系BQ.1.1、XBB.1和CH.1.1显著的抗体逃逸
Natl Sci Rev. 2023 May 23;10(8):nwad148. doi: 10.1093/nsr/nwad148. eCollection 2023 Aug.
本文引用的文献
1
Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants.奥密克戎 XBB.1.5、CH.1.1 和 CA.3.1 变异株增强了对中和抗体反应的逃避。
Cell Rep. 2023 May 30;42(5):112443. doi: 10.1016/j.celrep.2023.112443. Epub 2023 Apr 18.
2
Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate.抗新型冠状病毒变异株奥密克戎XBB.1.5的抗病毒和二价疫苗效力
Lancet Infect Dis. 2023 Apr;23(4):402-403. doi: 10.1016/S1473-3099(23)00070-1. Epub 2023 Feb 8.
3
ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5.XBB.1.5增强传播性中的ACE2结合与抗体逃逸
Lancet Infect Dis. 2023 Mar;23(3):278-280. doi: 10.1016/S1473-3099(23)00010-5. Epub 2023 Feb 3.
4
Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎XBB.1.5变体的传播性、感染性和免疫抗性增强。
Lancet Infect Dis. 2023 Mar;23(3):280-281. doi: 10.1016/S1473-3099(23)00051-8. Epub 2023 Jan 31.
5
Antiviral Agents against Omicron Subvariant BA.4.6 In Vitro. Reply.针对奥密克戎亚型BA.4.6的体外抗病毒药物。回复。
N Engl J Med. 2023 Feb 2;388(5):e12. doi: 10.1056/NEJMc2216611.
6
Antiviral Agents against Omicron Subvariant BA.4.6 In Vitro.针对奥密克戎亚变体BA.4.6的体外抗病毒药物
N Engl J Med. 2023 Feb 2;388(5):e12. doi: 10.1056/NEJMc2216611.
7
Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution.印迹 SARS-CoV-2 体液免疫诱导奥密克戎 RBD 进化趋同。
Nature. 2023 Feb;614(7948):521-529. doi: 10.1038/s41586-022-05644-7. Epub 2022 Dec 19.
8
Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB.抗病毒药物对奥密克戎亚型BQ.1.1和XBB的疗效
N Engl J Med. 2023 Jan 5;388(1):89-91. doi: 10.1056/NEJMc2214302. Epub 2022 Dec 7.
9
Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75.抗病毒药物对奥密克戎亚型BA.2.75的疗效。
N Engl J Med. 2022 Sep 29;387(13):1236-1238. doi: 10.1056/NEJMc2209952. Epub 2022 Sep 7.
Zotero 插件